{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:24Z","timestamp":1794013284983,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jacc.2019.03.513","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T13:58:35Z","timestamp":1560175115000},"page":"2961-2970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Efficacy and Safety of Evolocumab in\u00a0Chronic Kidney Disease in the FOURIER\u00a0Trial"],"prefix":"10.1016","volume":"73","author":[{"given":"David M.","family":"Charytan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando Lira","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders G.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.03.513_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib4","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.513_bib5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib6","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1681\/ASN.2016090957","article-title":"Benefit of ezetimibe added to simvastatin in reduced kidney function","volume":"28","author":"Stanifer","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.03.513_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.03.513_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.03.513_bib14","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.03.513_bib15","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1001\/jama.286.12.1494","article-title":"Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models","volume":"286","author":"Ghali","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.03.513_bib16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.03.513_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.03.513_bib18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.03.513_bib19","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1097\/01.ASN.0000135969.33773.0B","article-title":"\u201cRenalism\u201d: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency","volume":"15","author":"Chertow","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.03.513_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.ajkd.2005.11.017","article-title":"Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective","volume":"47","author":"Sosnov","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2019.03.513_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2008.11.010","article-title":"Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"205","author":"Huskey","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2019.03.513_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.03.513_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2019.06.041","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719349034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719349034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T13:11:30Z","timestamp":1597842690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719349034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0735109719349034"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.03.513","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736004879.793562581","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Evolocumab in\u00a0Chronic Kidney Disease in the FOURIER\u00a0Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.03.513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}